EUVIMEDEUVIMED entdecken
VergleichsstudieOpen Access

Valve‐in‐Valve TAVR Versus Redo Surgery in Women With Degenerated Aortic Bioprosthesis: A Single‐Center Experience

Marco Tagliafierro iD, Rahul Kanade, Darina Kirilina, Fady Soliman, Isao Anzai, Susheel Kodali, Torsten Vahl, Rebecca Hahn, Tamim Nazif, Arnar Geirsson, Hiroo Takayama, Michael Argenziano und 3 weitere

Catheterization and Cardiovascular Interventions · 2026-08 · 108 (2) · 627-635

DOI: 10.1002/ccd.70693 ↗

Kurz gefasst

Vergleichsstudie in der Zeitschrift Catheterization and Cardiovascular Interventions, online erschienen am 12.06.2026. Verfasst von Marco Tagliafierro und 14 weiteren Autor:innen. Beteiligte Einrichtung: Department of Surgery, Columbia University College of Physicians and Surgeons, New York-Presbyterian Hospital, New York, New York, USA. Hauptthemen laut MEDLINE: Bioprosthesis, Heart Valve Prosthesis, Aortic Valve, Reoperation. Die Arbeit nennt 24 Literaturangaben. Der Volltext ist frei in PubMed Central verfügbar.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Background

Bioprosthetic aortic valves require reinterventions once they degenerate. Options include redo‐surgical aortic valve replacement (redoSAVR) and Valve‐in‐Valve transcatheter aortic valve replacement (ViV). Women with valvular disease have historically demonstrated higher procedural risks and worse outcomes compared to men. There is a knowledge gap regarding outcomes of aortic valve reinterventions in women.

Aims

We sought to compare outcomes of ViV versus redoSAVR in women with degenerated bioprosthetic surgical valves.

Methods

Consecutive female patients with prior SAVR undergoing isolated ViV or redoSAVR between 2015 and 2025 were included. Primary endpoints were 30‐day all‐cause mortality, stroke, and major adverse cardiac events (MACE). Secondary (1‐year) endpoints included mortality, stroke, MACE, pacemaker implantation, and cardiac rehospitalization. Propensity score matching (PSM), Cox regression for survival, and Kaplan‐Meier for MACE were performed.

Results

Forty redoSAVR and 92 ViV female patients were included. ViV females were older, had lower BMI, and higher STS‐PROM. Primary endpoints were not significantly different between ViV and redoSAVR: mortality 1 (1.1%) versus 1 (2.5%), p = 0.303; stroke 3 (3.3%) versus 2 (5.0%), p = 0.480; MACE 3 (3.3%) versus 3 (7.5%), p = 0.272. 1‐year endpoints were also comparable: mortality 8 (8.7%) versus 3 (7.5%), p = 0.867; stroke 4 (4.3%) versus 2 (5.0%), p = 0.834; MACE 11 (12.0%) versus 5 (12.5%), p = 0.888; pacemaker 3 (3.3%) versus 1 (2.5%), p = 0.792; rehospitalization 10 (10.9%) versus 2 (5.0%), p = 0.265). Results were consistent before and after PSM.

Conclusions

ViV and redoSAVR in women yielded similar short‐term outcomes. Both represent valid options for treatment of degenerated aortic bioprosthesis.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

BioprosthesisHeart Valve ProsthesisAortic ValveReoperationTranscatheter Aortic Valve ReplacementHeart Valve Prosthesis ImplantationProsthesis FailureAortic Valve StenosisHumansFemaleRisk FactorsTime FactorsAgedTreatment OutcomeAged, 80 and overRisk AssessmentProsthesis DesignSex FactorsRetrospective Studies

Autor:innen und Institutionen

  • Department of Surgery, Columbia University College of Physicians and Surgeons, New York-Presbyterian Hospital, New York, New York, USA.
  • Department of Surgery, Center for Innovation and Outcomes Research, Columbia University, New York, New York, USA.
  • Department of Medicine, Columbia University College of Physicians and Surgeons, New York-Presbyterian Hospital, New York, New York, USA.

ORCID-Profile: Marco Tagliafierro

Zitieren

APA

Tagliafierro, M., Kanade, R., Kirilina, D., Soliman, F., Anzai, I., Kodali, S., Vahl, T., Hahn, R., Nazif, T., Geirsson, A., Takayama, H., Argenziano, M., Kurlansky, P., George, I., & Pirelli, L. (2026). Valve‐in‐Valve TAVR Versus Redo Surgery in Women With Degenerated Aortic Bioprosthesis: A Single‐Center Experience. Catheterization and Cardiovascular Interventions, 108(2), 627-635. https://doi.org/10.1002/ccd.70693

Vancouver

Tagliafierro M, Kanade R, Kirilina D, Soliman F, Anzai I, Kodali S, et al. Valve‐in‐Valve TAVR Versus Redo Surgery in Women With Degenerated Aortic Bioprosthesis: A Single‐Center Experience. Catheterization and Cardiovascular Interventions. 2026;108(2):627-635. doi:10.1002/ccd.70693

BibTeX
@article{Tagliafierro2026,
  author = {Tagliafierro, Marco and Kanade, Rahul and Kirilina, Darina and Soliman, Fady and Anzai, Isao and Kodali, Susheel and Vahl, Torsten and Hahn, Rebecca and Nazif, Tamim and Geirsson, Arnar and Takayama, Hiroo and Argenziano, Michael and Kurlansky, Paul and George, Isaac and Pirelli, Luigi},
  title = {Valve‐in‐Valve TAVR Versus Redo Surgery in Women With Degenerated Aortic Bioprosthesis: A Single‐Center Experience},
  journal = {Catheterization and Cardiovascular Interventions},
  year = {2026},
  volume = {108},
  number = {2},
  pages = {627--635},
  doi = {10.1002/ccd.70693}
}
Kostenlos starten →